Trials / Completed
CompletedNCT02552953
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Cyclacel Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm, dose escalation study in patients with advanced cancers.
Detailed description
This is an open-label, single arm, dose escalation study in patients with advanced cancers. Treatment will be administered on an outpatient basis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CYC065 |
Timeline
- Start date
- 2015-09-28
- Primary completion
- 2022-10-04
- Completion
- 2023-08-25
- First posted
- 2015-09-17
- Last updated
- 2024-05-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02552953. Inclusion in this directory is not an endorsement.